Managing acute myeloid leukaemia during the COVID-19 pandemic

Meet the Expert: Daniel Seymour

Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Treating patients with multiple myeloma in the real world

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

New CAR T therapy for relapsed and refractory ALL

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia

Maintenance treatment in multiple myeloma: A new era